Sitagliptin phosphate monohydrate

Therapeutic profile Sitagliptin is used in the treatment of type 2 diabetes 

Sitagliptin phosphate monohydrate (1, 7-[(3i )-3-amino-l-oxo-4-(2,4,5-trifluoro-phenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a]pyrazine phosphate monohydrate, Januvia ) is an oral hypoglycaemic drug, an inhibitor of the dipeptidyl peptidase-IV (DPP4) enzyme. It is widely used in the therapy of type 2 diabetes mellitus [1,2]. 

---

Although many effective DPP4 inhibitors contain an a-amino acid moiety [8], the p-amino acid-based inhibitors proved to be the most interesting [9]. Sitagliptin phosphate monohydrate (1) is an outstanding representative of this latter group of DPP4 inhibitors. 

A monohydrate of sitagliptin phosphate was first isolated from isoamyl alcohol saturated with water during investigations into isolation procedures which would reproducibly yield only Form I. With the monohydrate form isolated, all anhydrous and solvated crystalline phases were converted to crystaUine monohydrate in water or solvents with sufficiently high water activities given sufficient time. This very stable form had only one polymorph as well as excellent water solubility and particle characteristics, morphology, and flow-ability, that allowed for its easy replacement of Forms I, II, and III in the formulation process. 

---